Alfonso Arrazate

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Thijs J. Hagenbeek, Marc Hafner, Rana Mroue et al. · Nature Cancer · 2023 · 195 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +17

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

James D. Joseph, Beatrice Darimont, Wei Zhou et al. · eLife · 2016 · 119 citations · Full text

Medicine, Oncology, Pharmacology +15

Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors

Alexander M. Taylor, Bret R. Williams, Fabrizio Giordanetto et al. · Journal of Medicinal Chemistry · 2023 · 43 citations · Full text

Medicine, Oncology, Pharmacology +16

IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody

Ji Li, Ryan Ybarra, Judy Mak et al. · Clinical Cancer Research · 2018 · 42 citations · Full text

Medicine, Immunology, Oncology +17

Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity

Po‐Chang Chiang, Stephen E. Gould, Michelle Nannini et al. · Nanoscale Research Letters · 2014 · 15 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17